Spontaneous B-cell lymphoma in the cranial mediastinal lymph node of an aged male C57BL/6J mouse.

J Toxicol Pathol

Safety Research Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation, 2-26-1 Muraoka-Higashi, Fujisawa-shi, Kanagawa 251-8555, Japan.

Published: October 2024

B-cell lymphoma is generally observed in the spleen, mesenteric lymph nodes, and Peyer's patches in aged mice and rarely appears in other organs. Herein, we report a case of spontaneous B-cell lymphoma originating from the cranial mediastinal lymph node in a male 75-week-old C57BL/6J mouse. Macroscopically, a white mass was found at the base of the heart with no connection to the thymus. Microscopic examination revealed a solid proliferation of tumor cells with large nuclei at the center of the mass. Some macrophages, normal-sized lymphocytes, and lymphatic sinuses were found in both central and peripheral areas. Immunohistochemical analysis showed positive staining for cluster of differentiation 19, paired box protein 5, immunoglobulin M, and Ki-67 but not for cytokeratin AE1/AE3. These findings were not completely consistent with the established mouse lymphoma classification, leading to a diagnosis of B-cell lymphoma originating from the cranial mediastinal lymph node. This case report is the first to document a B-cell lymphoma in the cranial mediastinal lymph nodes in an aged C57BL/6J mouse.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442265PMC
http://dx.doi.org/10.1293/tox.2023-0130DOI Listing

Publication Analysis

Top Keywords

b-cell lymphoma
20
cranial mediastinal
16
mediastinal lymph
16
lymph node
12
c57bl/6j mouse
12
spontaneous b-cell
8
lymphoma cranial
8
lymph nodes
8
lymphoma originating
8
originating cranial
8

Similar Publications

Treatment strategies for early stage diffuse large B-cell lymphoma (ES-DLBCL) include R-CHOP, with a similar schedule to that used in advanced stage, or a reduced number of cycles followed by radiation therapy (RT). We retrospectively analyzed 179 ES-DLBCL patients, managed according to the clinical practice. Treatment regimens include chemoimmunotherapy 4-6 cycles +/- RT as consolidation.

View Article and Find Full Text PDF

Objective: Patients with hematological malignancies have an elevated risk of developing pneumonia after contracting COVID-19. Lymphoma is the most prevalent hematologic malignancy. It is critical to identify patients at high risk of contracting COVID-19-associated pneumonia.

View Article and Find Full Text PDF

Primary large B-cell lymphoma of the central nervous system misdiagnosed as autoimmune encephalitis: a case report.

Front Oncol

January 2025

Department of 2ndBrain Center and Stroke Center, The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, China.

Primary central nervous system lymphomas (PCNSL) are rare, constituting 2 - 3% of intracranial malignancies. A 49-year-old male presented with a 20-day history of dizziness and a 15-day history of right-sided weakness. Physical examination revealed various abnormal signs.

View Article and Find Full Text PDF

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of B-cell non-Hodgkin's lymphoma (NHL), up to 30%-40% of patients will relapse and 10%-15% of patients have primary refractory disease, so exploring new treatment options is necessary. Ferroptosis is a non-apoptotic cell death mode discovered in recent years. Its occurrence pathway plays an essential impact on the therapeutic effect of tumors.

View Article and Find Full Text PDF

Background: Mantle cell lymphoma is a diverse B-cell lymphoma with varying clinical behaviors. Treating relapsed or refractory mantle cell lymphoma is challenging, with Bruton's tyrosine kinase inhibitors proving effective but not curative. Post-Bruton's tyrosine kinase inhibitor failure, the prognosis remains unfavorable.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!